PAT Rs 29.90 Crore | RPG Life Sciences Q4 FY26 Results
- May 1, 2026
- Posted by: Neeraj Pandey
- Category: News
RPG Life Sciences announced its Q4 FY26 financial results on April 29, 2026, posting PAT of Rs 29.90 crore, higher year-on-year, as the Pharmaceuticals and API company delivered its January to March 2026 quarter earnings. RPG Life Sciences Q4 FY26 results are closely tracked by investors as a key indicator of the company’s performance trajectory. This article covers the RPG Life Sciences Q4 FY26 financial highlights, performance analysis, full year FY26 summary, management outlook, and frequently asked questions on RPG Life Sciences Q4 results.
RPG Life Sciences Q4 FY26 Financial Highlights
RPG Life Sciences reported Q4 FY26 net profit of Rs 29.90 crore, higher year-on-year, on the back of consistent branded generic pharmaceutical sales growth in India. The board recommended a dividend of Rs 24 per equity share (300 percent on Rs 8 face value) for FY26, with June 19, 2026 set as the record date. Shares jumped 14 percent post results on the strong dividend announcement. The board recommended a dividend of Rs 24 per share (300 percent on Rs 8 face value) for FY26.
| Metric | Q4 FY26 | Q4 FY25 | YoY Change |
|---|---|---|---|
| Revenue / Total Income | As per NSE/BSE exchange filing | Refer NSE/BSE filing | Grew YoY |
| PAT | Rs 29.90 crore | Refer NSE/BSE filing | Higher YoY |
| Full Year FY26 PAT | Refer annual filing | Refer filing | As reported |
| Dividend (FY26) | Rs 24 per share (300 percent on Rs 8 face value) | Refer filing | FY26 final |
Also Read: Bhansali Engineering Polymers Q4 FY26 Results
RPG Life Sciences Q4 FY26 Performance Analysis
RPG Life Sciences Q4 FY26 branded pharmaceutical business maintained consistent prescription demand across its cardiology, CNS, and anti-infective portfolio. The domestic prescription market’s growth and field force productivity drove RPG Life Sciences Q4 FY26 India revenues.
RPG Life Sciences Q4 FY26 dividend of Rs 24 per share is a significant yield return for shareholders and reflects the company’s strong cash generation and capital return commitment. Shares rallied 14 percent post results, validating investor appreciation for the generous payout.
RPG Life Sciences Full Year FY26 Business Summary
FY26 was a year of steady performance for RPG Life Sciences with consistent profitability from the domestic branded generics business. The company maintained its branded franchise through doctor engagement and pharmacy distribution investments.
RPG Life Sciences Q4 FY26 Outlook and FY27 Priorities
RPG Life Sciences FY27 strategy focuses on branded generic portfolio expansion in therapy-focused segments, scaling API exports, and improving operational efficiency at manufacturing facilities. The Rs 24 dividend signals confidence in sustaining strong cash flows.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and insightful research pieces!
Conclusion
The RPG Life Sciences Q4 FY26 results provide investors with the company’s January to March 2026 performance data. RPG Life Sciences Q4 FY26 PAT of Rs 29.90 crore reflects the operational performance in the Pharmaceuticals and API sector. Investors tracking RPG Life Sciences Q4 results should review the complete audited financials on NSE and BSE exchange filings before making any investment decision. RPG Life Sciences Q4 FY26 is an important milestone in the company’s annual earnings calendar.
This article on RPG Life Sciences Q4 FY26 results is for informational and educational purposes only. It is not investment advice. Please consult a SEBI registered investment advisor before making any investment decision. Past performance is not indicative of future results.
Frequently Asked Questions on RPG Life Sciences Q4 FY26 Results
What were the RPG Life Sciences Q4 FY26 results?
RPG Life Sciences Q4 FY26 results were announced on April 29, 2026. The company reported PAT of Rs 29.90 crore for the January to March 2026 quarter. RPG Life Sciences Q4 FY26 details are in the official NSE and BSE exchange filings.
What was RPG Life Sciences Q4 FY26 PAT?
RPG Life Sciences Q4 FY26 PAT was Rs 29.90 crore, higher YoY. The RPG Life Sciences Q4 FY26 results were announced on April 29, 2026, at the board of directors meeting to approve audited financials.
What was RPG Life Sciences Q4 FY26 revenue?
RPG Life Sciences Q4 FY26 revenue was As per NSE/BSE exchange filing. Investors should refer to the NSE and BSE exchange filing for the full audited RPG Life Sciences Q4 FY26 revenue breakdown and segmental performance data.
Did RPG Life Sciences declare a dividend after Q4 FY26 results?
Yes, RPG Life Sciences declared a dividend of Rs 24 per share (300 percent on Rs 8 face value) as part of the Q4 FY26 results announcement, subject to shareholder approval at the AGM.
What is the outlook for RPG Life Sciences after Q4 FY26?
RPG Life Sciences FY27 strategy focuses on branded generic portfolio expansion in therapy-focused segments, scaling API exports, and improving operational efficiency at manufacturing facilities. The Rs 24 dividend signals confidence in sustaining str… Investors should monitor management commentary and quarterly filings for updated guidance on RPG Life Sciences Q4 FY26 performance sustainability into FY27.
How did RPG Life Sciences Q4 FY26 compare year on year?
RPG Life Sciences Q4 FY26 PAT of Rs 29.90 crore was higher YoY. The year-on-year comparison for RPG Life Sciences Q4 FY26 versus Q4 FY25 is available in the official audited NSE and BSE exchange filings.
What sector does RPG Life Sciences operate in?
RPG Life Sciences operates in the Pharmaceuticals and API sector in India and is listed on NSE and BSE. RPG Life Sciences Q4 FY26 results reflect the broader Pharmaceuticals and API sector trends for the January to March 2026 quarter. Contextualising RPG Life Sciences Q4 performance within industry dynamics requires reviewing sector-level data alongside management commentary.
Is RPG Life Sciences a good investment after Q4 FY26 results?
Whether RPG Life Sciences is a good investment after the RPG Life Sciences Q4 FY26 results depends on your individual financial goals, risk tolerance, and investment horizon. RPG Life Sciences Q4 FY26 results provide one data point on the company’s trajectory. Always consult a SEBI registered financial advisor before making any investment decision.
Recent Article
Torrent Power Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
Usha Martin Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
Triveni Engineering and Industries Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
Utkarsh Small Finance Bank Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
Venus Pipes and Tubes Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook
